| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8790130 | Urologic Oncology: Seminars and Original Investigations | 2018 | 11 Pages | 
Abstract
												These studies demonstrate the immunomodulatory properties of M7824 on both tumor cell phenotype and immune-mediated lysis. Compared to anti-PD-L1 or M7824mut, M7824 induces immunogenic modulation of urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. These findings show the relevance of the dual blockade of PD-L1 and TGFβ in urothelial carcinoma cell lines and thus support the rationale for future clinical studies of M7824 in patients with urothelial cancer.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Oncology
												
											Authors
												Italia M.D., Renee N. Ph.D., Morgan L. B.S., Lauren M. Ph.D., Mario M.D., Ph.D., Marijo M.D., Ph.D., Jeffrey Ph.D., 
											